

NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES

## NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001 (CTH)

PYC Therapeutics Limited (Company) has today issued new fully paid ordinary shares (New Shares) pursuant to the institutional placement announced on 2 February 2026.

The Company gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Act) as notionally modified by Australian Securities and Investments Commission (ASIC) Corporations (Disregarding Technical Relief) Instrument 2016/73 (ASIC Instrument 2016/73) that:

1. the Company has issued 85,489,067 New Shares without disclosure to investors under Part 6D.2 of the Act;
2. as at the date of this notice, the Company has complied with:
  - the provisions of Chapter 2M of the Act as they apply to the Company (accounting requirements); and
  - sections 674 and 674A of the Act (continuous disclosure requirements); and
3. as at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) or 708A(8) of the Act that is required to be set out in this notice under section 708A(6)(e) of the Act.

Where applicable, references in this notice to sections of the Act are to those sections as modified by ASIC Instrument 2016/73.

### About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development <sup>1</sup>.

For more information, visit [pyctx.com](https://pyctx.com), or follow us on [LinkedIn](#).

---

<sup>1</sup> Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank  
<https://doi.org/10.1101/2020.11.02.2022232>

*This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited*

## **CONTACT US**

**Investor relations and media contact**  
[investor@pyctx.com](mailto:investor@pyctx.com)

